Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What may be happening today is any institutional holder of IPCI is closing their position.
Making up fantasy exit points to make one look not as bad is funny. LOL.
If I had bought any of those 75 cent warrants I’d be super-po’ed right now. I looked up “screwed” in the dictionary and it said when a company has 30 million 75 cent warrants and needs their share price to go from 40 cents to a dollar in the next few weeks to avoid delisting then they are totally screwed. Really. Of course, the dictionary doesn’t know about the cunning plan to maybe someday sell drugs in Malaysia and Vietnam, maybe.
Just checking in, are we at $5 yet?
I cannot believe approval of this 25 cent drug with 10 competitors hasn't sent the SP to $5 by now. Manipulation! Probably they don't release the PR because they don't want to point out that they are about to extract over $1M cash from IPCI treasury by taking their hilarious ANDA approval bonuses.
What's a million or so pre-funded warrants among friends?
Stay tuned for the next pump: Nasal/oral HAL study results will be described in a PR as a great success, but no data will be revealed to prove it is true.
("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths.
Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.
This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.
That was out before the big run yesterday afternoon.
Why?
GNBT was .03 when that video was out. I sure wish I had put $100 in at that time.
Great day!
I love new approval days most of all. A real thing that we own that we didn't own before yesterday. And more to come! Soon! Filling the buckets, one ANDA at a time. And credit where credit is due: in the cases of Norco and Percocet, Nasrat turned a bad thing into something good. These ANDA's were originally developed as NDA's with 2 bead ADF. The FDA made clear they were not interested in ADF versions of the acetaminophen combination products, and so Nasrat then smartly transitioned to the non-ADF generics. It took time, but now here we are, and instead of jack squat, we've got these two shiny new ANDA's. Personally, I hope we eventually see NDA filings for the 2 bead ADF versions of these drugs, but the unfortunate truth is, these nonADF versions will probably make a shit-ton more money than the ADF versions ever would have.
I'm looking forward to the imminent approvals for the SunGen CNS stimulants, yet another example of management's foresight about problems in the ADF market. I agree ELTP's stagnant SP sucks, but I also know that other ADF companies are going down in flames while Elite's future has never looked better. Today is a great day for ELTP longs, and I credit Nasrat for it.
Yes, I'm sure you do.
I wonder how much You lost on ALL your stocks,that would be entertaining :o) How the rest of Yours doing,all of them trading at all time low ? :)
I can real off 4-5 ways to short pennies that go back decades and still exist today
Youre welcome
signed,
Super Genius
Just FYI
WED DEC 5TH is the safe day to sell. GNBT IS moving to NASDAQ By Dec read the last 8K. AT NASDAQ 8K will with PR will stabilized GNBT TO 20usd to50Per shares by Dec 2019 100USD.
Going Concern
The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $410 and $446 million and a working capital deficiency of approximately $24 million and $21 million at July 31, 2018 and 2017, respectively. The Company has funded its activities to date almost exclusively from debt and equity financings.
The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners.
It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the balance sheet date.
Getting it ready...
Carter Ward:
Isradipine, which was one of those products, is already approved manufacture at Elite, and it is part of the Glenmark alliance.
In addition to Methadone, we're seeing improvement already in Isradipine forecast and sales since Glenmark took over this product last month, which will also provide significantly improved contributions over the past quarter.
Interesting, thanks for sharing.
It is more interesting what they will cover. Also, keep in mind, this is only one Blue Cross plan (Alabama).
https://www.al.com/news/2018/11/blue-cross-changes-opioid-coverage-drops-standard-oxycontin.html?outputType=amp
OxyContin and its generic version, oxycodone ER, will no longer be covered. But Xtampza ER, a new formulation of oxycodone ER, will be. Abusers often crush extended-release painkillers such as OxyContin into powder, to get more of the drug into their systems faster; various medical references describe Xtampza ER as a formulation designed to thwart that approach.
"Xtampza ER maintained its ER characteristics after crushing, unlike many other commercially available opioid formulations, including some formulated with abuse-deterrent properties," found one study. "As such, Xtampza ER may be less appealing to abusers and offer a margin of safety for patients who manipulate dosage forms to facilitate swallowing."
Blue Cross and Blue Shield also will cover Roxybond, "a new instant release OxyContin formulation that is considered 'abuse deterrent' by the FDA," the insurer said.
chart looks ready for a move imo ~
Don’t you think they would hint at positive results if it were the case during the MJ Fox symposium?
Speaking of track record... Isn't it about time for Odidi to pay someone to write an article about him how he was the force behind BIOVAL...
Big push above $1 will happen anytime now
Too bad...
Spare us your sour grapes and crawl back in your hole please. Lol
Be careful here.
NDA resubmission this Quarter will make this stock one of the cheapest FDA play . Garbage or not i dont care because most Biotechs with very low valuation running up fast before FDA decision and thats why im in .
Name a few...
Yes, trials & studies have halted many times due to positive results known well in advance of planned end date as great benefit to patients.
Lol.
IMO, if results were significant, the study would have been halted.
Tanya Simuni, MD , looks like it will be a poster display which is tricky to read into before hand.
The 12th Annual PD Therapeutics Conference will be held on October 25, 2018 at Convene Midtown East, New York City.
Anybody in NYC next week?
https://www.michaeljfox.org/research/parkinsons-therapeutics-conference.html?navid=pd-therapeutics-conf
The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 12th Annual PD Therapeutics Conference will be held on October 25, 2018 at Convene Midtown East, New York City.
We are delighted to have Carole Ho, MD chair our 2018 event.
The PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
2018 Posters
Nicolas Dzamko, PhD
The University of Sydney
Gert Geurtsen, PhD, MSc
Academic Medical Hospital of the University of Amsterdam
Martin Gill, PhD
Neuropore
Sarah Hamm-Alvarez, PhD
University of Southern California
Joohi Jiminez-Shahed, MD
Baylor College of Medicine
Robert Mach, PhD
University of Pennsylvania
Gary Miller, PhD
Emory University
Nicole Polinski, PhD
The Michael J. Fox Foundation
Shalini Padmanabhan, PhD
The Michael J. Fox Foundation
Tanya Simuni, MD
Northwestern University
Caryl Sortwell, PhD
Weston Brain Institute
Tanya Simuni, MD, directs the Northwestern University Feinberg School of Medicine’s Movement Disorders Center. She is the principal investigator on many Parkinson’s disease clinical trials and an expert on the design and coordination of multicenter studies. Dr. Simuni is leading a Phase III clinical trial evaluating isradipine as a potential disease-modifying agent in early Parkinson’s, which is supported by the National Institutes of Health.
Nasrat best not pull Isradipine from Epic with this "PD" trial about to conclude !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
He will not get the FDA to approve a site transfer for who knows how many YEARS and "IF" he ever did, market share will be gobbled up by Teva and others
If isradipine becomes a major drug for Elite, it will be 100% thanks to Nasrat. First, it is a Mikah drug. But even beyond that, this drug has been Nasrat's baby. It was the only drug of the 12 that were contracted with Epic that he took back from them. He let 10 of the 12 sit on the shelf, but isradipine he took back. He brought Doug Plassche over in good part because Doug was familiar with isradipine manufacturing. Even then, it was quite an ordeal to get it out the door. Quite a lot of trouble for a $5 million dollar drug, so no doubt, Nasrat understood the significance of this one old drug, certainly above all the other Mikah drugs. He made sure this drug got on the shelf, and if STEADY-PDIII results are good, Elite will do very well. Nasrat will deserve all of the credit.
The issues we encountered is the same issues that a lot public companies encounter. First, the API manufacturer was the only AP. We had single source API manufacturer in our application. So, in order for them to sell us product for us to go ahead and validate they requested first that we pay the PDUFA fee on their behalf. They were not using their DMF. So they wanted us to pay that. We paid it. It was like $36,000 or so.
Then they demanded that we buy all of the raw materials that go into making Isradipine. So we have to fork another check for $125,000 and then we had to buy the entire lot from them, which we did and the entire lot was API which is lot of API and a lot of negotiations took place between Doug Plassche and these people in order to finally to get us the API. Now that we have the API Doug needs a prioritize it and I anticipate that we will go ahead and finish that edition and launch in Q4 of this year.
Boyd has 3 different accounts holding IPCI shares
So does that mean Boyd was selling on October 11th and now has less shares than he started with after the r/s?
And if he did sell...how come the offering filing we read the other day stated that IPCI expected Boyd/Armistice to participate in the new offering?
Schedule 13G
A Schedule 13G is a shorter and simpler form than a Schedule 13D. Schedule 13G eligible filers include (i) qualified institutional investors; (ii) passive investors; and (iii) exempt investors. The full contents and instructions of a Schedule 13G can be found HERE.
Qualified Institutional Investors
Rule 13d-1 allows qualified institutional investors to file on Schedule 13G instead of 13D. A qualified institutional investor is an investor that acquired the securities in the ordinary course of business and not with the purpose nor with the effect of changing or influencing the control of the issuer and is also one of the following:
...
"bleh, bleh, bleh"
...
Qualified institutional investors must file a Schedule 13G within 10 days of the end of the month of the triggering event requiring the filing and must amend the Schedule 13G each year within 45 days of the end of the calendar year to report changes in beneficial ownership. However, if a 13G filing shareholder acquires in excess of 10% of the company’s stock, an amended 13G must be within 10 days of the acquisition. Moreover, an amendment must also be filed within 10 days to report increases or decreases of beneficial ownership of more than 5%
E-1 to E-7 to O-1 to O-4.
Interesting...
https://ir.intellipharmaceutics.com/press-releases/detail/181/intellipharmaceutics-announces-closing-of-us-14-3-million
resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01 per share (the "Pre-Funded Warrants"), and warrants exercisable for 20,000,000 common shares, at an exercise price of US$0.75 per share (the "Firm Warrants"). These securities were issued in units, each consisting of either one common share and one Firm Warrant or one Pre-Funded Warrant and one Firm Warrant, and were offered at a public offering price of US$0.75 per unit.
So what happens if they close below $1?
They already announced they met the 10-day share price above $1 requirement as of 9/28, but they also announced they were given an extension until 10/17 for the shareholder equity. What happens if today's closing price is below $1?
It already seems they'll have a tough time meeting the shareholder equity requirement. On today's filings, their shareholder deficit is nearly $5 million, which means they'll need $7.5 million in the bank, not including their routine operating costs, and nearly $2M of that deficit are loans from Odidi's. They could use those loans to buy into this offering, which would reduce the company's need to raise $2M and prevent the associated dilution. It is in his power to do it right now, this very minute, and the share price would go up by multiple dollars as soon as it was announced. No need to worry about $1 closing price. It also would reduce the need to find buyers, as it seems they are selling those "units" for substantially less than the $1.37 they suggest in the prospectus.
The only reason not to convert those loans into shares right now is if he believes bankruptcy is more likely than success.
I expect this company will need some material news regarding future revenue to generate the volume increase needed to propel the stock higher.
Pump, meet Dump
PTIE went 200% up today
Offering for about 7.5M shares at about $2.
The simple calc on Shareowner Equity is the sum of all assets minus the sum of all liabilities.
You are so right.
Good - now we can agree you bragging about saving thousands of lives was really BS.
2 - ADFs are an invariant, just a bunch of reaserch and money thrown away and therefore better to be removed from to avoid costs to the society
On September 28, 2018, Egalet Corporation (the “Company”) notified the U.S. Food and Drug Administration that, for business reasons, the Company is discontinuing the manufacture and promotion of Arymo® ER (morphine sulfate) extended-release tablets (“ARYMO ER”) effective September 28, 2018 (the “Discontinuation”). As part of its notice, the Company requested that the Orange Book staff move ARYMO ER to the “Discontinued Drug Products List” of the Approved Drug Products and Therapeutic Equivalence Evaluations (Orange Book) publication, and that the User Fee staff note the discontinued status of the product.
Good Lord #2
Previously you stated you saved thousands of lives by preventing this drug having this blue dye to be approved.
This sound's like you are quite sure about it and you have some proof.
Well - I understand this completely. You think you have saved lives.
If blue dye in oxycodone tablets shift abuse use to fentanyl, my opinion is there should be blue dye in fentanyl products too.
Do you possibly think it's dangerous to put blue dye in fentanyl plasters?
Keep waiting.
Meanwhile I still wait for you to clarify me, how many people would die if - let's say - 10,000 people would take blue dye containing pain killers.
I still suppose you don't answer simply because you don't know.
Oh good Lord, what????
so, we just do not know yet if they intend to meet that OR release news which pops the price and then we meet market cap requirements. They would not need to an additional offering as the registration they did in August would probably get them enough money if they released news which propped up share price.
remember what that did back in August. It reclassified those warrants as shares with the strike prices, so if we hit those targets which are $6,$7.50 and $12.50, those people just call in the shares and the company gets the funds.